Phase 1 Evaluation of PYX-106 in Patients with Solid Tumors

The primary objective of this Phase 1 study is to evaluate the safety and tolerability of **PYX-106** in patients with **solid tumors**. This is clinically relevant as it aims to determine the potential adverse effects and establish a safe dosage range for future studies, which is crucial for the development of effective cancer therapies. No secondary objectives are provided in the available data.

The clinical trial involves a total of **33 participants** diagnosed with **solid tumors**. The study population includes both male and female subjects, with an age range encompassing adults and older adults. Participants were selected to include a vulnerable population, although specific criteria for vulnerability are not detailed. The trial does not specify particular lifestyle considerations such as diet, physical activity, or habits. The sponsor has not provided detailed information regarding the main objective of the trial or the principal inclusion criteria. The health status of participants is not explicitly described beyond their diagnosis of solid tumors.

The clinical trial is a **Phase 1** study designed to evaluate the investigational product PYX-106 in patients with **solid tumors**. The trial employs a randomized, double-blind, and controlled design to ensure the reliability and validity of the results. The estimated duration of the trial spans from July 1, 2023, to December 31, 2024, allowing for comprehensive data collection and analysis over this period.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit is crucial for ensuring that only suitable candidates are enrolled in the study. Following successful screening, participants will be randomized into treatment groups and will attend regular follow-up visits. These visits are scheduled to monitor the participants' health, assess the efficacy and safety of the investigational product, and collect necessary data. The trial will conclude with an end-of-study visit, where final assessments will be conducted to evaluate the overall outcomes of the treatment.

The expected length of participant involvement in the trial is contingent upon the individual response to the treatment and adherence to the study protocol. Participants may be subject to early termination from the study if they experience adverse effects, fail to comply with the study requirements, or withdraw consent. The trial is conducted in accordance with ethical guidelines and regulatory standards to ensure the safety and well-being of all participants.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In this study, there is no mention of any **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment being used. The data does not provide details on any additional relevant information about drug administration, dosing schedules, or participant compliance monitoring. The absence of these details suggests that the trial documentation may be incomplete or that such information is not applicable to this particular study.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, with an estimated recruitment start date of July 1, 2023, and an estimated end date of December 31, 2024. Although specific efficacy parameters or endpoints are not detailed, Phase 1 trials typically focus on assessing safety, tolerability, and pharmacokinetics, which may indirectly inform efficacy assessments. The trial will likely involve systematic data collection and analysis at predetermined intervals, utilizing validated methods and instruments appropriate for the investigational product and the condition under study. The results will contribute to understanding the potential therapeutic effects and inform subsequent trial phases.